Heron Therapeutics
HRTX
99 hedge funds and large institutions have $851M invested in Heron Therapeutics in 2016 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 36 increasing their positions, 36 reducing their positions, and 21 closing their positions.
64% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $8.7M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
0% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 36
7% less funds holding
Funds holding: 107 → 99 (-8)
30% less capital invested
Capital invested by funds: $1.21B → $851M (-$363M)
38% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$32.6M |
| 2 |
VMI
VHCP Management II
New York
|
+$8.01M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$7.23M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$5.84M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$2.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$15.1M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$11.6M |
| 3 |
KCM
Kingdon Capital Management
New York
|
-$8.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.94M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.26M |
HRTX Hedge Fund Activity: Q1 2016 in Review
99 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2016, worth a combined $851M — down 30% from $1.21B a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of HRTX and 13 opened new positions — a net loss of 8 holders — while 36 trimmed existing stakes and 36 added.
The largest buyer was Franklin Resources, adding an estimated $32.6M. The largest seller was Broadfin Capital, cutting an estimated $15.1M.
- 99 institutional investors held Heron Therapeutics (HRTX) as of Q1 2016, down from 107 in Q4 2015.
- Funds reported $851M of Heron Therapeutics stock for Q1 2016, down 30% quarter-over-quarter.
- 13 funds opened new Heron Therapeutics positions in Q1 2016 and 21 closed out, a net change of -8 holders.
- The largest Heron Therapeutics buyer in Q1 2016 was Franklin Resources, an estimated $32.6M added.
- The largest Heron Therapeutics seller in Q1 2016 was Broadfin Capital, an estimated $15.1M sold.
Based on aggregated 13F filings for Q1 2016.